Qiagen N.V.
NYSE:QGEN · New York Stock Exchange
-$0.35 today
Vol 1.44M · Avg 2.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.2%
avg 7.2%
ROIC
7.8%
avg 4.5%
ROA
6.7%
avg 3.9%
Analysis
ROE is currently the strongest return metric at 11.2% versus its period average of 7.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thierry Bernard | Chief Executive Officer, MD & Member of Management Board | $2.43M | — | 62 | — | — |
Roland Sackers | Chief Financial Officer, MD & Member of Management Board | $1.33M | — | 58 | — | — |
Stephany Foster | Senior Vice President & Head of Human Resources | — | — | 47 | — | — |
John Gilardi | Vice President & Head of Corporate Communications | — | — | — | — | — |
Nitin Sood | Senior VP & Head of Product Portfolio & Innovation | — | — | 53 | — | — |
Thomas Theuringer | Senior Director & Head of External Communications | — | — | — | — | — |
Dominic John | Vice President of Marketing & Product Management | — | — | — | — | — |
Thomas Schweins | Senior Vice President of Life Science Business Area | — | — | — | — | — |
Antonio Santos | Senior Vice President & Head of Global Operations | — | — | — | — | — |
Daniel Wendorff CEFA CIIA | VP & Head of Investor Relations | — | — | — | — | — |
Jean-Pascal Viola | Senior Vice President & Head of Corporate Strategy and Business Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +0.0% | +12.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +0.7% | +4.9% (15yr)5 analysts |
| Net Income | N/A | N/A | +0.2% | +11.8% (15yr)5 analysts |
| EBIT | N/A | N/A | +1.9% | +8.4% (15yr)5 analysts |
Analysis
Recent growth has been strongest in EBIT at +1.9% over three years. Forward estimates point to EPS at +12.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Exelixis, Inc.
NASDAQ:EXEL
$13.26B
Align Technology, Inc.
NASDAQ:ALGN
$12.55B
ICON Public Limited Company
NASDAQ:ICLR
$11.08B
Revvity, Inc.
NYSE:RVTY
$10.98B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.71B
Baxter International Inc.
NYSE:BAX
$10.14B
The Ensign Group, Inc.
NASDAQ:ENSG
$9.08B
Charles River Laboratories International, Inc.
NYSE:CRL
$8.85B
Bio-Techne Corporation
NASDAQ:TECH
$8.64B
Hims & Hers Health, Inc.
NYSE:HIMS
$7.31B
Who manages QGEN?
Qiagen N.V. (QGEN) lists 11 active executives. The top listed executive is Thierry Bernard, Chief Executive Officer, MD & Member of Management Board.
Explore More
Continue the stock analysis
Jump to another research area for this company.